The good news is that the U.S. FDA’s complete response letter (CRL) for Venatorx Pharmaceuticals Inc.’s intravenous antibiotic combination, cefepime-taniborbactam, in complicated urinary tract infections (cUTIs) requested no additional clinical testing. The bad news is the inevitable delay for a drug Venatorx and partner Melinta Therapeutics Inc. are aiming to position as a much-needed option for the fight against drug-resistant gram-negative infections.
"DelveInsight Business Research LLP"DelveInsight's "Acute Pyelonephritis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Acute Pyelonephritis, historical and